Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

Condition:   Asthma
Interventions:   Biological: Mepolizumab;   Drug: Placebo;   Drug: SOC
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified October 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.